在肺腺癌中,Paeoniae radix通过极光 B 路径抑制克服了对EGFR-TKI的耐药性
Heerim Yeo1, Haeseung Lee2, Sang-Min Park1
1College of Pharmacy, Chungnam National University, Republic of Korea.
结合EGFR-TKIs的Paeoniae Radix (PR) 可能可以克服肺腺癌的耐药性. 这种天然产品抑制了Aurora B通路,增强了EGFR突变LUAD的亡和药物反应.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 表皮生长因子受体 (EGFR) 抑制剂改善了EGFR突变肺腺癌 (LUAD) 的结果.
- 对EGFR抑制剂的耐药性仍然是一个重大的临床挑战,限制了治疗疗效.
- 自然产品为克服治疗耐药性提供了潜在的途径.
研究的目的:
- 为了研究Paeoniae Radix (PR) 与第一代EGFR-氨酸激酶抑制剂 (TKI) 结合的协同效应,埃洛提尼布和格菲提尼布.
- 探索PR在克服LUAD中对EGFR-TKI获得的耐药性的潜力.
- 阐明组合治疗效果背后的分子机制.
主要方法:
- 用PR治疗的EGFR突变LUAD细胞系的转录组分析.
- 试验验证PR与erlotinib和gefitinib结合使用.
- 评估光激酶活性和亡诱导.
- 基因表达分析以确认路径调制.
主要成果:
- PR治疗逆转了与EGFR-TKI耐药性相关的基因特征.
- PR抑制了Aurora B通路,这是抵抗的关键调解者.
- 组合疗法增强了LUAD细胞对erlotinib和gefitinib的反应.
- 观察到抑制光激酶活性和诱导亡.
- 基因表达证实了极光B通路的抑制和亡通路的上调.
结论:
- 在克服LUAD耐药性方面,Paeoniae Radix与EGFR-TKI具有协同作用.
- 组合疗法准了Aurora B通路,并促进了亡.
- PR代表了一种有希望的天然产品,用于开发针对LUAD的EGFR-TKI耐药性的新疗法.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Mitogens and the Cell Cycle
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
